Dublin, June 28, 2019 (GLOBE NEWSWIRE) -- The "Trelegy Ellipta" report has been added to ResearchAndMarkets.com's offering.

Trelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy.

The product contains the same ICS/LABA components as Breo ([fluticasone furoate + vilanterol]; GlaxoSmithKline/Innoviva), plus a LAMA component, umeclidinium bromide.

GlaxoSmithKline received approval for Trelegy Ellipta in chronic obstructive pulmonary disease in Q3 2017, and is currently evaluating the drug in asthma patients whose symptoms are inadequately controlled by ICS/LABA therapies.

Key Topics Covered

1. Drug Overview
2. Product Profiles
3. Trelegy Ellipta: Chronic obstructive pulmonary disease (COPD)
4. Trelegy Ellipta: Asthma

List of Figures
Figure 1: Trelegy Ellipta for COPD - SWOT analysis
Figure 2: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 3: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 4: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Trelegy Ellipta for asthma - SWOT analysis
Figure 6: The authors drug assessment summary of Trelegy Ellipta in asthma
Figure 7: The authors drug assessment summary of Trelegy Ellipta in asthma
Figure 8: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Trelegy Ellipta drug profile
Table 2: Trelegy Ellipta Phase III data in COPD
Table 3: Trelegy Ellipta Phase III trial in COPD
Table 4: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Trelegy Ellipta drug profile
Table 6: Trelegy Ellipta Phase III trials in asthma
Table 7: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/qr36ar

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.